{"id":"https://openalex.org/W2014018534","doi":"https://doi.org/10.1007/s00262-014-1610-3","title":"Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-\u03b1 pathways","display_name":"Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-\u03b1 pathways","alternate_titles":[],"publication_year":2014,"publication_date":"2014-10-07","ids":{"openalex":"https://openalex.org/W2014018534","doi":"https://doi.org/10.1007/s00262-014-1610-3","mag":"2014018534","pmid":"https://pubmed.ncbi.nlm.nih.gov/25287778","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4282702"},"language":"en","primary_location":{"id":"doi:10.1007/s00262-014-1610-3","doi":"https://doi.org/10.1007/s00262-014-1610-3","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00262-014-1610-3","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00262-014-1610-3.pdf","source":{"id":"https://openalex.org/S203303425","display_name":"Cancer Immunology Immunotherapy","issn_l":"0340-7004","issn":["0340-7004","1432-0851"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Immunology, Immunotherapy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2014018534"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s00262-014-1610-3.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078553844","display_name":"Balaji Balasa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405280693","display_name":"AbbVie Biotherapeutics (United States)","ror":"https://ror.org/03a0g6939","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688","https://openalex.org/I4405280693"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Balaji Balasa","raw_affiliation_strings":["Abbott Biotherapeutics Corp., Redwood City, CA, USA","Abbott Biotherapeutics Corp., Redwood City, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abbott Biotherapeutics Corp., Redwood City, CA, USA","institution_ids":["https://openalex.org/I4405280693"]},{"raw_affiliation_string":"Abbott Biotherapeutics Corp., Redwood City, USA","institution_ids":["https://openalex.org/I4405280693"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113149932","display_name":"Rui Yun","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405280693","display_name":"AbbVie Biotherapeutics (United States)","ror":"https://ror.org/03a0g6939","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688","https://openalex.org/I4405280693"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Rui Yun","raw_affiliation_strings":["AbbVie Biotherapeutics Inc., Redwood City, CA, USA","AbbVie Biotherapeutics Inc., Redwood City, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Biotherapeutics Inc., Redwood City, CA, USA","institution_ids":["https://openalex.org/I4405280693"]},{"raw_affiliation_string":"AbbVie Biotherapeutics Inc., Redwood City, USA","institution_ids":["https://openalex.org/I4405280693"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112905592","display_name":"Nicole A. Belmar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405280693","display_name":"AbbVie Biotherapeutics (United States)","ror":"https://ror.org/03a0g6939","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688","https://openalex.org/I4405280693"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Nicole A. Belmar","raw_affiliation_strings":["AbbVie Biotherapeutics Inc., Redwood City, CA, USA","AbbVie Biotherapeutics Inc., Redwood City, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Biotherapeutics Inc., Redwood City, CA, USA","institution_ids":["https://openalex.org/I4405280693"]},{"raw_affiliation_string":"AbbVie Biotherapeutics Inc., Redwood City, USA","institution_ids":["https://openalex.org/I4405280693"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026089535","display_name":"Melvin Fox","orcid":"https://orcid.org/0000-0003-2109-036X","observed_orcids":["https://orcid.org/0000-0003-2109-036X"]},"institutions":[{"id":"https://openalex.org/I4405280693","display_name":"AbbVie Biotherapeutics (United States)","ror":"https://ror.org/03a0g6939","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688","https://openalex.org/I4405280693"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Melvin Fox","raw_affiliation_strings":["AbbVie Biotherapeutics Inc., Redwood City, CA, USA","AbbVie Biotherapeutics Inc., Redwood City, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Biotherapeutics Inc., Redwood City, CA, USA","institution_ids":["https://openalex.org/I4405280693"]},{"raw_affiliation_string":"AbbVie Biotherapeutics Inc., Redwood City, USA","institution_ids":["https://openalex.org/I4405280693"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066438477","display_name":"Debra T. Chao","orcid":"https://orcid.org/0000-0002-8814-3406","observed_orcids":["https://orcid.org/0000-0002-8814-3406"]},"institutions":[{"id":"https://openalex.org/I4405280693","display_name":"AbbVie Biotherapeutics (United States)","ror":"https://ror.org/03a0g6939","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688","https://openalex.org/I4405280693"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Debra T. Chao","raw_affiliation_strings":["AbbVie Biotherapeutics Inc., Redwood City, CA, USA","AbbVie Biotherapeutics Inc., Redwood City, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Biotherapeutics Inc., Redwood City, CA, USA","institution_ids":["https://openalex.org/I4405280693"]},{"raw_affiliation_string":"AbbVie Biotherapeutics Inc., Redwood City, USA","institution_ids":["https://openalex.org/I4405280693"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004501595","display_name":"Michael D. H. Robbins","orcid":"https://orcid.org/0000-0001-5012-0623","observed_orcids":["https://orcid.org/0000-0001-5012-0623"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michael D. Robbins","raw_affiliation_strings":["Bristol-Myers Squibb, Princeton, NJ, USA","Bristol Myers Squibb, Princeton, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022587464","display_name":"Gary C. Starling","orcid":"https://orcid.org/0000-0001-9879-4336","observed_orcids":["https://orcid.org/0000-0001-9879-4336"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]},{"id":"https://openalex.org/I4405280693","display_name":"AbbVie Biotherapeutics (United States)","ror":"https://ror.org/03a0g6939","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688","https://openalex.org/I4405280693"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gary C. Starling","raw_affiliation_strings":["Abbott Biotherapeutics Corp., Redwood City, CA, USA","Merck Research Labs, Palo Alto, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abbott Biotherapeutics Corp., Redwood City, CA, USA","institution_ids":["https://openalex.org/I4405280693"]},{"raw_affiliation_string":"Merck Research Labs, Palo Alto, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5088339230","display_name":"Audie G. Rice","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]},{"id":"https://openalex.org/I4405280693","display_name":"AbbVie Biotherapeutics (United States)","ror":"https://ror.org/03a0g6939","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688","https://openalex.org/I4405280693"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Audie G. Rice","raw_affiliation_strings":["AbbVie Biotherapeutics Inc., Redwood City, CA, USA","Medical Science Liaison, USP Medical \u2013 Oncology, Research & Development, Bristol-Myers Squibb Company, 777 Scudders Mill Road, Plainsboro, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Biotherapeutics Inc., Redwood City, CA, USA","institution_ids":["https://openalex.org/I4405280693"]},{"raw_affiliation_string":"Medical Science Liaison, USP Medical \u2013 Oncology, Research & Development, Bristol-Myers Squibb Company, 777 Scudders Mill Road, Plainsboro, USA","institution_ids":["https://openalex.org/I4210091812"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5088339230"],"corresponding_institution_ids":["https://openalex.org/I4210091812","https://openalex.org/I4405280693"],"apc_list":{"value":4590,"currency":"USD","value_usd":4590},"apc_paid":{"value":4590,"currency":"USD","value_usd":4590},"fwci":9.5693,"has_fulltext":true,"cited_by_count":163,"citation_normalized_percentile":{"value":0.98528029,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":100},"biblio":{"volume":"64","issue":"1","first_page":"61","last_page":"73"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9434000253677368,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9434000253677368,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11020","display_name":"Immune Cell Function and Interaction","score":0.04879999905824661,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.004399999976158142,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/elotuzumab","display_name":"elotuzumab","score":1.0},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.9390000104904175},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9490000009536743},{"id":"https://openalex.org/keywords/natural-killer-cells","display_name":"natural killer cells","score":0.8629999756813049},{"id":"https://openalex.org/keywords/nk-cell-activation","display_name":"NK cell activation","score":0.8859999775886536},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.9819999933242798},{"id":"https://openalex.org/keywords/slamf7","display_name":"SLAMF7","score":0.9599999785423279},{"id":"https://openalex.org/keywords/interleukin-2","display_name":"interleukin-2","score":0.8270000219345093},{"id":"https://openalex.org/keywords/tnf-alpha","display_name":"TNF-\u03b1","score":0.8109999895095825},{"id":"https://openalex.org/keywords/il-2-receptor-alpha","display_name":"IL-2 receptor alpha","score":0.9079999923706055},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6840000152587891},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.7350000143051147}],"concepts":[{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5798318982124329},{"id":"https://openalex.org/C40677261","wikidata":"https://www.wikidata.org/wiki/Q21418091","display_name":"Antibody-dependent cell-mediated cytotoxicity","level":4,"score":0.503847062587738},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.48328760266304016},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.46602463722229004},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3354301452636719},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.32259827852249146},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.22351506352424622},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.1682882010936737}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000920","descriptor_name":"Antibody-Dependent Cell Cytotoxicity","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D005434","descriptor_name":"Flow Cytometry","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007124","descriptor_name":"Immunoenzyme Techniques","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007376","descriptor_name":"Interleukin-2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D007694","descriptor_name":"Killer Cells, Natural","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D007694","descriptor_name":"Killer Cells, Natural","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D007694","descriptor_name":"Killer Cells, Natural","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008213","descriptor_name":"Lymphocyte Activation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D014407","descriptor_name":"Tumor Cells, Cultured","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014409","descriptor_name":"Tumor Necrosis Factor-alpha","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D016513","descriptor_name":"Mice, SCID","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1007/s00262-014-1610-3","doi":"https://doi.org/10.1007/s00262-014-1610-3","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00262-014-1610-3","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00262-014-1610-3.pdf","source":{"id":"https://openalex.org/S203303425","display_name":"Cancer Immunology Immunotherapy","issn_l":"0340-7004","issn":["0340-7004","1432-0851"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Immunology, Immunotherapy","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:3257312","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4282702","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:4282702","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4282702/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Immunol Immunother","raw_type":"Text"},{"id":"pmid:25287778","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25287778","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer immunology, immunotherapy : CII","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1007/s00262-014-1610-3","doi":"https://doi.org/10.1007/s00262-014-1610-3","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s00262-014-1610-3","pdf_url":"https://link.springer.com/content/pdf/10.1007/s00262-014-1610-3.pdf","source":{"id":"https://openalex.org/S203303425","display_name":"Cancer Immunology Immunotherapy","issn_l":"0340-7004","issn":["0340-7004","1432-0851"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Immunology, Immunotherapy","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320333023","display_name":"AbbVie Biotherapeutics","ror":"https://ror.org/03a0g6939"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2014018534.pdf","grobid_xml":"https://content.openalex.org/works/W2014018534.grobid-xml"},"referenced_works_count":40,"referenced_works":["https://openalex.org/W1491044166","https://openalex.org/W1547504566","https://openalex.org/W1669828090","https://openalex.org/W1964370179","https://openalex.org/W1966397617","https://openalex.org/W1969110349","https://openalex.org/W1971412620","https://openalex.org/W1972276563","https://openalex.org/W1973223101","https://openalex.org/W1974680874","https://openalex.org/W1985745837","https://openalex.org/W1988327939","https://openalex.org/W1994721812","https://openalex.org/W2000047150","https://openalex.org/W2000130439","https://openalex.org/W2004543856","https://openalex.org/W2006735414","https://openalex.org/W2031134093","https://openalex.org/W2035331552","https://openalex.org/W2044835347","https://openalex.org/W2047832163","https://openalex.org/W2082050806","https://openalex.org/W2086278185","https://openalex.org/W2099308699","https://openalex.org/W2105522483","https://openalex.org/W2110544227","https://openalex.org/W2119810076","https://openalex.org/W2121099992","https://openalex.org/W2128644254","https://openalex.org/W2135404380","https://openalex.org/W2141502099","https://openalex.org/W2145896029","https://openalex.org/W2146001019","https://openalex.org/W2156047731","https://openalex.org/W2162494273","https://openalex.org/W2167757748","https://openalex.org/W2172026936","https://openalex.org/W2586331836","https://openalex.org/W3195431600","https://openalex.org/W4252175385"],"related_works":["https://openalex.org/W7095241317","https://openalex.org/W2888864405","https://openalex.org/W2948718798","https://openalex.org/W2899811391","https://openalex.org/W2467352880","https://openalex.org/W2786794342","https://openalex.org/W1040554665","https://openalex.org/W2624831991","https://openalex.org/W2969812779","https://openalex.org/W2086278185"],"abstract_inverted_index":{"Elotuzumab":[0,115],"is":[1,241],"a":[2,47],"humanized":[3],"monoclonal":[4],"antibody":[5],"specific":[6],"for":[7],"signaling":[8],"lymphocytic":[9],"activation":[10,92,174,199,216],"molecule-F7":[11],"(SLAMF7,":[12],"also":[13],"known":[14],"as":[15,46],"CS1,":[16],"CD319,":[17],"or":[18,65,206],"CRACC)":[19],"that":[20,166,226],"enhances":[21],"natural":[22],"killer":[23],"(NK)":[24],"cell-mediated":[25,238],"antibody-dependent":[26],"cellular":[27],"cytotoxicity":[28,110],"(ADCC)":[29],"of":[30,86,91,130,171],"SLAMF7-expressing":[31],"myeloma":[32,41,68,112,121,158,201,218,233],"cells.":[33],"This":[34],"study":[35],"explored":[36],"the":[37,84,169],"mechanisms":[38],"underlying":[39],"enhanced":[40,157,243],"cell":[42,77,113,122,126,147,159,164,198,202,215,219,234],"killing":[43,160],"with":[44,53,63,168,204,221,246],"elotuzumab":[45,87,131,205,207,227],"single":[48],"agent":[49,153],"and":[50,88,94,106,109,119,144,173,185,200,210,217,231],"in":[51,61,71,124,142,145,149],"combination":[52,85,129,156],"lenalidomide,":[54,209],"to":[55,82],"support":[56],"ongoing":[57],"phase":[58],"III":[59],"trials":[60],"patients":[62],"relapsed/refractory":[64],"newly-diagnosed":[66],"multiple":[67],"(MM).":[69],"An":[70],"vitro":[72,150],"peripheral":[73],"blood":[74],"lymphocyte":[75],"(PBL)/myeloma":[76],"co-culture":[78,192],"model":[79],"was":[80,97],"developed":[81],"evaluate":[83],"lenalidomide.":[89,247],"Expression":[90],"markers":[93],"adhesion":[95,172],"receptors":[96],"evaluated":[98],"by":[99,104,111,161,182],"flow":[100],"cytometry,":[101],"cytokine":[102],"expression":[103],"Luminex":[105],"ELISPOT":[107],"assays,":[108,193],"counts.":[114],"activated":[116],"NK":[117,163,197,214,229,237],"cells":[118,230],"promoted":[120],"death":[123,203,220,235],"PBL/myeloma":[125,146],"co-cultures.":[127],"The":[128,155],"plus":[132,208],"lenalidomide":[133],"demonstrated":[134],"superior":[135],"anti-myeloma":[136],"activity":[137],"on":[138],"established":[139],"MM":[140],"xenografts":[141],"vivo":[143],"co-cultures":[148],"than":[151],"either":[152],"alone.":[154],"modulating":[162],"function":[165],"coincided":[167],"upregulation":[170],"markers,":[175],"including":[176],"interleukin":[177],"(IL)-2R\u03b1":[178],"expression,":[179],"IL-2":[180],"production":[181],"CD3(+)CD56(+)":[183],"lymphocytes,":[184],"tumor":[186],"necrosis":[187],"factor":[188],"(TNF)-\u03b1":[189],"production.":[190],"In":[191],"TNF-\u03b1":[194,212],"directly":[195],"increased":[196],"neutralizing":[211],"decreased":[213],"elotuzumab.":[222],"These":[223],"results":[224],"demonstrate":[225],"activates":[228],"induces":[232],"via":[236],"ADCC,":[239],"which":[240],"further":[242],"when":[244],"combined":[245]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2014018534","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":9},{"year":2024,"cited_by_count":15},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":15},{"year":2021,"cited_by_count":11},{"year":2020,"cited_by_count":12},{"year":2019,"cited_by_count":16},{"year":2018,"cited_by_count":19},{"year":2017,"cited_by_count":24},{"year":2016,"cited_by_count":20},{"year":2015,"cited_by_count":10}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
